Early Detection and Diagnosis

You have full text access to this OnlineOpen article

A three-gene expression signature model to predict clinical outcome of clear cell renal carcinoma

  1. Masahiro Yao1,†,*,
  2. Ying Huang1,
  3. Koichi Shioi1,
  4. Keiko Hattori1,
  5. Takayuki Murakami1,
  6. Futoshi Sano1,
  7. Masaya Baba1,
  8. Keiichi Kondo1,
  9. Noboru Nakaigawa1,
  10. Takeshi Kishida1,
  11. Yoji Nagashima2,
  12. Hisafumi Yamada-Okabe3,
  13. Yoshinobu Kubota1

Article first published online: 10 JUN 2008

DOI: 10.1002/ijc.23641

Issue

International Journal of Cancer

International Journal of Cancer

Volume 123, Issue 5, pages 1126–1132, 1 September 2008

Additional Information

How to Cite

Yao, M., Huang, Y., Shioi, K., Hattori, K., Murakami, T., Sano, F., Baba, M., Kondo, K., Nakaigawa, N., Kishida, T., Nagashima, Y., Yamada-Okabe, H. and Kubota, Y. (2008), A three-gene expression signature model to predict clinical outcome of clear cell renal carcinoma. Int. J. Cancer, 123: 1126–1132. doi: 10.1002/ijc.23641

Author Information

  1. 1

    Department of Urology and Molecular Genetics, Yokohama City University Graduate School of Medicine, Yokohama, Japan

  2. 2

    Department of Molecular Pathology and Oncology, Yokohama City University Graduate School of Medicine, Yokohama, Japan

  3. 3

    Pharmaceutical Research Department III, Chugai Research Laboratories, Chugai Pharmaceutical Co. Ltd., Kamakura, Japan

  1. †

    Fax: +81-45-786-5775.

*Department of Urology and Molecular Genetics, Yokohama City University Graduate School of Medicine, 3-9 Fukuura, Kanazawa-ku, Yokohama 236-0004, Japan

Publication History

  1. Issue published online: 17 JUN 2008
  2. Article first published online: 10 JUN 2008
  3. Manuscript Accepted: 6 MAR 2008
  4. Manuscript Received: 4 SEP 2007

Funded by

  • Ministry of Education, Culture, Sports, Science and Technology of Japan. Grant Number: 18591764
  • Strategic Research Project, Yokohama City University, Japan. Grant Numbers: K17017, K18029, K19036, K19008
  • Yokohama City University Center of Excellence Program, Ministry of Education, Culture, Sports, Science and Technology of Japan. Grant Number: 301200780
  • Japanese Government (Monbukagakusho:MEXT). Grant Number: 074454

SEARCH

SEARCH BY CITATION

ARTICLE TOOLS

View Full Article with Supporting Information (HTML) Get PDF (264K)

References

  • 1
    Cohen HT,McGovern FJ. Renal-cell carcinoma. N Engl J Med 2005; 353: 2477–90.
  • 2
    Garcia JA,Rini BI. Recent progress in the management of advanced renal cell carcinoma. CA Cancer J Clin 2007; 57: 112–25.
    Direct Link:
  • 3
    Bukowski RM,Negrier S,Elson P. Prognostic factors in patients withadvanced renal cell carcinoma: development of an international kidney cancer working group. Clin Cancer Res 2004; 10: 6310S–14S.
  • 4
    Lam JS,Shvarts O,Leppert JT,Figlin RA,Belldegrun AS. Renal cell carcinoma 2005: new frontiers in staging, prognostication and targeted molecular therapy. J Urol 2005; 173: 1853–62.
  • 5
    Shuch BM,Lam JS,Belldegrun AS,Figlin RA. Prognostic factors in renal cell carcinoma. Semin Oncol 2006; 33: 563–75.
  • 6
    Linehan WM,Zbar B. Focus on kidney cancer. Cancer Cell 2004; 6: 223–8.
  • 7
    Russo P. Surgical intervention in patients with metastatic renal cancer: current status of metastasectomy and cytoreductive nephrectomy. Nat Clin Pract Urol 2004; 1: 26–30.
  • 8
    Latif F,Tory K,Gnarra J,Yao M,Duh F-M,Orcutt ML,Stackhouse T,Kuzmin I,Modi W,Geil L,Schmidt L,Zhou F, et al. Identification of the von Hippel-Lindau disease tumor suppressor gene. Science 1993; 260: 1317–20.
  • 9
    Kaelin WGJr. The von Hippel-Lindau tumor suppressor protein and clear cell renal carcinoma. Clin Cancer Res 2007; 13: 680s–4s
  • 10
    Bucca G,Carruba G,Saetta A,Muti P,Castagnetta L,Smith CP. Gene expression profiling of human cancers. Ann N Y Acad Sci 2004; 1028: 28–37.
    Direct Link:
  • 11
    Wadlow R,Ramaswamy S. DNA microarrays in clinical cancer research. Curr Mol Med 2005; 5: 111–20.
  • 12
    Quackenbush J. Microarray analysis and tumor classification. N Engl J Med 2006; 354: 2463–72.
  • 13
    Rosenwald A,Wright G,Chan WC,Connors JM,Campo E,Fisher RI,Gascoyne RD,Muller-Hermelink HK,Smeland EB,Giltnane JM,Hurt EM,Zhao H, et al. The use of molecular profiling to predict survival after chemotherapy for diffuse large-B-cell lymphoma. N Engl J Med 2002; 346: 1937–47.
  • 14
    Lossos IS,Czerwinski DK,Alizadeh AA,Wechser MA,Tibshirani R,Botstein D,Levy R. Prediction of survival in diffuse large-B-cell lymphoma based on the expression of six genes. N Engl J Med 2004; 350: 1828–37.
  • 15
    Chen HY,Yu SL,Chen CH,Chang GC,Chen CY,Yuan A,Cheng CL,Wang CH,Terng HJ,Kao SF,Chan WK,Li HN, et al. Five-gene signature and clinical outcome in non-small-cell lung cancer. N Engl J Med 2007; 356: 11–20.
  • 16
    Yao M,Tabuchi H,Nagashima Y,Baba M,Nakaigawa N,Ishiguro H,Hamada K,Inayama Y,Kishida T,Hattori K,Yamada-Okabe H,Kubota Y. Gene expression analysis of renal carcinoma: adipose differentiation-related protein as a potential diagnostic and prognostic biomarker for clear-cell renal carcinoma. J Pathol 2005; 205: 377–87.
    Direct Link:
  • 17
    Golub TR,Slonim DK,Tamayo P,Huard C,Gaasenbeek M,Mesirov JP,Coller H,Loh ML,Downing JR,Caligiuri MA,Bloomfield CD,Lander ES. Molecular classification of cancer: class discovery and class prediction by gene expression monitoring. Science 1999; 286: 531–7.
  • 18
    Tamayo P,Slonim D,Mesirov J,Zhu Q,Kitareewan S,Dmitrovsky E,Lander ES,Golub TR. Interpreting patterns of gene expression with self-organizing maps: methods and application to hematopoietic differentiation. Proc Natl Acad Sci USA 1999; 96: 2907–12.
  • 19
    Guinan P,Sobin LH,Algaba F,Badellino F,Kameyama S,MacLennan G,Novick A. TNM staging of renal cell carcinoma: workgroup No. 3. Union Internationale Contre le Cancer (UICC) and the American Joint Committee on Cancer (AJCC). Cancer 1997; 80: 992–3.
    Direct Link:
  • 20
    Shioi K,Komiya A,Hattori K,Huang Y,Sano F,Murakami T,Nakaigawa N,Kishida T,Kubota Y,Nagashima Y,Yao M. Vascular cell adhesion molecule 1 predicts cancer-free survival in clear cell renal carcinoma patients. Clin Cancer Res 2006; 12: 7339–46.
  • 21
    Yao M,Huang Y,Shioi K,Hattori K,Murakami T,Nakaigawa N,Kishida T,Nagashima Y,Kubota Y. Expression of adipose differentiation-related protein: a predictor of cancer-specific survival in clear cell renal carcinoma. Clin Cancer Res 2007; 13: 152–60.
  • 22
    Lamb GW,McMillan DC,Ramsey S,Aitchison M. The relationship between the preoperative systemic inflammatory response and cancer-specific survival in patients undergoing potentially curative resection for renal clear cell cancer. Br J Cancer 2006; 94: 781–4.
  • 23
    Takahashi M,Rhodes DR,Furge KA,Kanayama H,Kagawa S,Haab BB,Teh BT. Gene expression profiling of clear cell renal cell carcinoma: gene identification and prognostic classification. Proc Natl Acad Sci USA 2001; 98: 9754–9.
  • 24
    Vasselli JR,Shih JH,Iyengar SR,Maranchie J,Riss J,Worrell R,Torres-Cabala C,Tabios R,Mariotti A,Stearman R,Merino M,Walther MM, et al. Predicting survival in patients with metastatic kidney cancer by gene-expression profiling in the primary tumor. Proc Natl Acad Sci USA 2003; 100: 6958–63.
  • 25
    Sültmann H,von Heydebreck A,Huber W,Kuner R,Buness A,Vogt M,Gunawan B,Vingron M,Füzesí L,Poustka A. Gene expression in kidney cancer is associated with cytogenetic abnormalities, metastasis formation, and patient survival. Clin Cancer Res 2005; 11: 646–55.
  • 26
    Kosari F,Parker AS,Kube DM,Lohse CM,Leibovich BC,Blute ML,Cheville JC,Vasmatzis G. Clear cell renal cell carcinoma: gene expression analyses identify a potential signature for tumor aggressiveness. Clin Cancer Res 2005; 11: 5128–39.
  • 27
    Jones J,Otu H,Spentzos D,Kolia S,Inan M,Beecken WD,Fellbaum C,Gu X,Joseph M,Pantuck AJ,Jonas D,Libermann TA. Gene signatures of progression and metastasis in renal cell cancer. Clin Cancer Res 2005; 11: 5730–9.
  • 28
    Saito S,Yamashita S,Endoh M,Yamato T,Hoshi S,Ohyama C,Watanabe R,Ito A,Satoh M,Wada T,Paulson JC,Arai Y, et al. Clinical significance of ST3Gal IV expression in human renal cell carcinoma. Oncol Rep 2002; 9: 1251–5.
  • 29
    Kondo T,Ito F,Nakazawa H,Horita S,Osaka Y,Toma H. High expression of chemokine gene as a favorable prognostic factor in renal cell carcinoma. J Urol 2004; 171: 2171–5.
  • 30
    Takenawa J,Kaneko Y,Kishishita M,Higashitsuji H,Nishiyama H,Terachi T,Arai Y,Yoshida O,Fukumoto M,Fujita J. Transcript levels of aquaporin 1 and carbonic anhydrase IV as predictive indicators for prognosis of renal cell carcinoma patients after nephrectomy. Int J Cancer 1998; 79: 1–7.
    Direct Link:
  • 31
    Hedberg Y,Davoodi E,Roos G,Ljungberg B,Landberg G. Cyclin-D1 expression in human renal-cell carcinoma. Int J Cancer 1999; 84: 268–72.
    Direct Link:
  • 32
    Yang CC,Chu KC,Yeh WM. Expression of vascular endothelial growth factor in renal cell carcinoma is correlated with cancer advancement. J Clin Lab Anal 2003; 17: 85–9.
    Direct Link:
  • 33
    Nelson J,Bagnato A,Battistini B,Nisen P. The endothelin axis: emerging role in cancer. Nat Rev Cancer 2003; 3: 110–6.
  • 34
    Bagnato A,Natali PG. Endothelin receptors as novel targets in tumor therapy. J Transl Med 2004; 2: 16.
  • 35
    Battistini B,Berthiaume N,Kelland NF,Webb DJ,Kohan DE. Profile of past and current clinical trials involving endothelin receptor antagonists: the novel “-sentan” class of drug. Exp Biol Med 2006; 231: 653–95.
  • 36
    Bittner M,Meltzer P,Chen Y,Jiang Y,Seftor E,Hendrix M,Radmacher M,Simon R,Yakhini Z,Ben-Dor A,Sampas N,Dougherty E, et al. Molecular classification of cutaneous malignant melanoma by gene expression profiling. Nature 2000; 406: 536–40.
  • 37
    Bagnato A,Rosano L,Spinella F,Di Castro V,Tecce R,Natali PG. Endothelin B receptor blockade inhibits dynamics of cell interactions and communications in melanoma cell progression. Cancer Res 2004; 64: 1436–43.
  • 38
    Eltze E,Bertolin M,Korsching E,Wülfing P,Maggino T,Lelle R. Expression and prognostic relevance of endothelin-B receptor in vulvar cancer. Oncol Rep 2007; 18: 305–11.
  • 39
    Wulfing C,Eltze E,Yamini J,Wulfing P,Bierer S,Bocker W,Hertle L,Semjonow A,Sievert KD. Expression of the endothelin axis in bladder cancer: relationship to clinicopathologic parameters and long-term survival. Eur Urol 2005; 47: 593–600.
  • 40
    Carducci MA,Jimeno A. Targeting bone metastasis in prostate cancer with endothelin receptor antagonists. Clin Cancer Res 2006; 12: 6296s–300s
  • 41
    Van Sant C,Wang G,Anderson MG,Trask OJ,Lesniewski R,Semizarov D. Endothelin signaling in osteoblasts: global genome view and implication of the calcineurin/NFAT pathway. Mol Cancer Ther 2007; 6: 253–61.
  • 42
    Douglas ML,Richardson MM,Nicol DL. Endothelin axis expression is markedly different in the two main subtypes of renal cell carcinoma. Cancer 2004; 100: 2118–24.
    Direct Link:
  • 43
    Pflug BR,Zheng H,Udan MS,D'Antonio JM,Marshall FF,Brooks JD,Nelson JB. Endothelin-1 promotes cell survival in renal cell carcinoma through the ET(A) receptor. Cancer Lett 2007; 246: 139–48.
  • 44
    Herrmann E,Eltze E,Bierer S,Bogemann M,Brinkmann OA,Balnowair H,Hertle L,Wulfing C. Expression of the Endothelin-axis in the different histologic subtypes of renal cell carcinoma: a tissue microarray analysis. Oncol Rep 2007; 17: 275–80.
  • 45
    Wieland T,Mittmann C. Regulators of G-protein signalling: multifunctional proteins with impact on signalling in the cardiovascular system. Pharmacol Ther 2003; 97: 95–115.
  • 46
    Furuya M,Nishiyama M,Kimura S,Suyama T,Naya Y,Ito H,Nikaido T,Ishikura H. Expression of regulator of G protein signalling protein 5 (RGS5) in the tumour vasculature of human renal cell carcinoma. J Pathol 2004; 203: 551–8.
    Direct Link:
  • 47
    Berger M,Bergers G,Arnold B,Hammerling GJ,Ganss R. Regulator of G-protein signaling-5 induction in pericytes coincides with active vessel remodeling during neovascularization. Blood 2005; 105: 1094–101.
  • 48
    Ostman A,Heldin CH. PDGF receptors as targets in tumor treatment. Adv Cancer Res 2007; 97: 247–74.
  • 49
    Motzer RJ,Hutson TE,Tomczak P,Michaelson MD,Bukowski RM,Rixe O,Oudard S,Negrier S,Szczylik C,Kim ST,Chen I,Bycott PW, et al. Sunitinib versus interferon alfa in metastatic renal-cell carcinoma. N Engl J Med 2007; 356: 115–24.
  • 50
    Escudier B,Eisen T,Stadler WM,Szczylik C,Oudard S,Siebels M,Negrier S,Chevreau C,Solska E,Desai AA,Rolland F,Demkow T, et al. Sorafenib in advanced clear-cell renal-cell carcinoma. N Engl J Med 2007; 356: 125–34.
  • 51
    Dupuy A,Simon RM. Critical review of published microarray studies for cancer outcome and guidelines on statistical analysis and reporting. J Natl Cancer Inst 2007; 99: 147–57.
View Full Article with Supporting Information (HTML) Get PDF (264K)